army China Chinese Coronavirus Covid-19 IPR media intelligence Medicine military News Media Patent Tianjin Vaccine World Health Organization
The Chinese State Intellectual Property Office (SIPO) approved the first patent for a COVID-19 vaccine candidate ࢀ" still in the third phase of testing ࢀ" which could ࢀœbe mass-produced in a short period of time,ࢀ the local press reported today. This vaccine, developed by the Military Scientific Institute and the Chinese biopharmaceutical company CanSino Biologics, began to be used in late June in the Chinese Army after a team led by researcher Chen Wei discovered a highly efficient neutralizing monoclonal antibody. Follow the latest hour on the coronavirus crisis The results of the second phase of the clinical trials of…
News Timeline:
Track the development of this news story across the Internet.